Brandon Guerrero, from Compton, in California, receives both a flu and a vaccine coded at the CVS in Huntington Park, California, August 28, 2024.
Christina House | Los Angeles Times | Getty images
Food and Drug Administration Tuesday has described new regulatory advice for future Boosters in the COVVI-19 vaccine, establishing stricter approval standards for healthy Americans.
The agency said that it wanted to see new clinical trials showing coated plans are always safe and effective before approving them for adults and healthy children, a new costly requirement for pharmaceutical companies that could limit that gets new blows each year. Previously, the FDA has generally approved each year of cocovated shots updated for all Americans on the basis of simple tests which show that they trigger a sufficiently strong antibody response.
“The truth is that for most of that, for many Americans, we simply do not know the answer to know whether or not they should obtain the seven, eight or nine or ten, because current policy would make us,” said Vinay Prasad, a frank critic of the pharmaceutical industry that was appointed Tuesday to direct the agency division that monitors vaccines, during a Tuesday town hall.
The FDA has recommended various standards of proof of approval on the risk of patients to become seriously ill from COVVID, according to an article published Tuesday in the New England Journal of Medicine. The authors of the newspaper are the commissioner of the FDA, Marty Makary and Prasad.
“The new COVVI-19 philosophy of the FDA represents a balance of regulatory flexibility and a commitment to the standard sciences,” said the agency in the newspaper. “The FDA will approve vaccines for high -risk people and, at the same time, will require robust and standard data on low -risk people.
The new guidelines are involved as secretary to health and social services Robert F. Kennedy Jr., an eminent vaccination skeptic, revised the country's health agencies and American vaccination policy.
For adults over 65 and over, and for people as young as 6 months who have certain underlying health conditions, the FDA has declared that it would accept immunogenicity data – which shows that a vaccine generates a strong immune response – as sufficient to determine that the advantages suddenly prevail. The FDA estimates that 100 to 200 million Americans have conditions that present them at high risk of serious illness, including obesity and mental health problems such as depression.
“There will be a quick regulatory path for these products to arrive on the market” for this age group, said Prasad during the town hall.
But for healthy people between 6 months and 64 years old who have no risk factors, the FDA plans to require higher evidence of vaccines from randomized and placebo trials. This means that some people would receive real shooting while others get an inactive substance as a saline stroke, to compare the results.
The main objective of the trials should be to show that shots help prevent the symptomatic covid, data showing at least 30% of efficiency, according to the document. People who have had covus in the past should always be included in the trial to better reflect the general population, said the newspaper.
Medication manufacturers will have to follow participants for at least six months “to ensure that early booster gains persist,” they added.
“Our policy also balances the need for evidence,” wrote Makary and Prasad in the newspaper. “We simply do not know if a 52-year-old healthy woman with a normal BMI who had covid-19 three times and received six previous doses of a COVVI-19 vaccine will benefit from the seventh dose.”
The FDA said that when it would approve a cocvid vaccine for high-risk people, it will encourage manufacturers to conduct randomized controlled clinical trials in healthy adults as part of their post-commercialization commitment for the photo.
During the town hall, Prasad suggested that annual updates to the vaccinations hiding may not be necessary, saying that the virus “lies at a slower” pace than the flu. He said he expects the FDA to need randomized clinical trials for boosters wearing every few years or “as long” rather than studies each year.
“The virus has no calendar,” he said, adding, “why don't we let science tell us when we have to change” shots to adapt to a major change in the virus.
The FDA rejects the approach of a single size
The document argued that the approach to the vaccine policy covid of the country of the country, which recommends annual fire for all Americans over six months, is exceeded and no longer complies with other countries. All other high income nations limit vaccine recommendations to the elderly or to high risk of serious illness due to COVID, the newspaper said.
The document indicates that the advantage of repeated vaccinations is “uncertain”, especially in low -risk patients who have developed a certain immune protection through shots, previous infections or both. The document said many Americans and healthcare providers “do not remain convinced of this advantage, pointing to Centers for Disease Control and Prevention on the decrease in vaccination rates in the United States for annual cocovan boosters.
The article has cited CDC data which indicate that in the past two seasons, less than 25% of Americans have received a COVVI-19 shot, including less than 10% of children and less than 50% of adults over the age of 75. Less than a third of health workers have received updated COVVI Boosters in the 2023 season to 2024, the document said, citing CDC data.
The document also suggested that recommendations for wide-shaped vaccinations each year have contributed to the decline in trust in vaccination, including in the measles-rubine vaccine. However, the document called MMR vaccines “clearly established as safe and very effective”.